Oruka Therapeutics Inc (ORKA)

$27.25 +0.12 (0.44%)
Market Cap 1.13B
Revenue (ttm) 0.00
Net Income (ttm) -83.72M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 166,100
Avg Vol 392,010
Day's Range N/A - N/A
Shares Out 41.54M
Stochastic %K 55%
Beta -0.29
Analysts Strong Sell
Price Target $43.62

Company Profile

Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 1 trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORK...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 606 7910
Website: orukatx.com
Address:
855 Oak Grove Avenue, Suite 100, Menlo Park, United States
fedeblu
fedeblu Oct. 20 at 5:00 PM
$ORKA give me 30!
0 · Reply
Pika_Capital
Pika_Capital Oct. 14 at 4:59 PM
$ORKA pay attention to amount of watchers ;)
0 · Reply
Pika_Capital
Pika_Capital Oct. 14 at 2:44 PM
$ORKA $APGE $SYRE reminder
0 · Reply
fedeblu
fedeblu Oct. 14 at 2:39 PM
$ORKA booommm
0 · Reply
thesheiktrader
thesheiktrader Oct. 14 at 2:39 PM
$ORKA join papa Noel for Christmas
0 · Reply
fedeblu
fedeblu Oct. 13 at 1:05 PM
$ORKA boom
0 · Reply
JarvisFlow
JarvisFlow Oct. 13 at 12:08 PM
Barclays has adjusted their stance on Oruka Therapeutics ( $ORKA ), setting the rating to Overweight with a target price of 48.
0 · Reply
LudicrousReturns
LudicrousReturns Oct. 10 at 1:18 PM
09 OCT 2025 Ludicrous Returns Stock Model Update New Buy Now: $IDAI, $ORKA, $BURU
0 · Reply
LanjutTBK
LanjutTBK Oct. 10 at 8:11 AM
$ORKA looks like $28 is next resistance
0 · Reply
thesheiktrader
thesheiktrader Oct. 9 at 8:03 PM
$ORKA do I miss?
1 · Reply
Latest News on ORKA
Oruka Therapeutics Announces $180 Million Private Placement

Sep 17, 2025, 1:02 AM EDT - 5 weeks ago

Oruka Therapeutics Announces $180 Million Private Placement

Oruka Therapeutics Announces Positive Interim Phase 1 Results for ORKA-001

Sep 17, 2025, 1:00 AM EDT - 5 weeks ago

Oruka Therapeutics Announces Positive Interim Phase 1 Results for ORKA-001

Oruka Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 11, 2025, 4:04 PM EDT - 2 months ago

Oruka Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Oruka Therapeutics Announces IND Clearance for EVERLAST-A Phase 2a Trial of ORKA-001 in Psoriasis with Phase 1 Data to be Presented at EADV in September

Jul 21, 2025, 7:00 AM EDT - 3 months ago

Oruka Therapeutics Announces IND Clearance for EVERLAST-A Phase 2a Trial of ORKA-001 in Psoriasis with Phase 1 Data to be Presented at EADV in September

Oruka Therapeutics Announces Promotion of Laura Sandler to Chief Operating Officer

Jul 1, 2025, 4:01 PM EDT - 4 months ago

Oruka Therapeutics Announces Promotion of Laura Sandler to Chief Operating Officer

Oruka Therapeutics to Present at the Jefferies Global Healthcare Conference

May 21, 2025, 7:00 AM EDT - 5 months ago

Oruka Therapeutics to Present at the Jefferies Global Healthcare Conference

Oruka Therapeutics Announces First Participants Dosed in Phase 1 Trial of ORKA-002, its Novel Half-life Extended Anti-IL-17A/F Antibody

May 20, 2025, 4:01 PM EDT - 5 months ago

Oruka Therapeutics Announces First Participants Dosed in Phase 1 Trial of ORKA-002, its Novel Half-life Extended Anti-IL-17A/F Antibody

Oruka Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 14, 2025, 4:15 PM EDT - 5 months ago

Oruka Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

Oruka Therapeutics to Present at Bank of America Securities 2025 Health Care Conference

Apr 29, 2025, 7:00 AM EDT - 6 months ago

Oruka Therapeutics to Present at Bank of America Securities 2025 Health Care Conference

Oruka Therapeutics Announces Preclinical Data for ORKA-002 at the 2025 American Academy of Dermatology Annual Meeting

Mar 7, 2025, 8:30 AM EST - 8 months ago

Oruka Therapeutics Announces Preclinical Data for ORKA-002 at the 2025 American Academy of Dermatology Annual Meeting

Oruka Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Mar 6, 2025, 4:09 PM EST - 8 months ago

Oruka Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Oruka Therapeutics to Present at Multiple March Investor Conferences

Feb 19, 2025, 7:00 AM EST - 8 months ago

Oruka Therapeutics to Present at Multiple March Investor Conferences

Oruka Therapeutics Announces First Participants Dosed in Phase 1 Trial of ORKA-001, its Novel Half-life Extended Anti-IL-23p19 Antibody

Dec 19, 2024, 7:00 AM EST - 11 months ago

Oruka Therapeutics Announces First Participants Dosed in Phase 1 Trial of ORKA-001, its Novel Half-life Extended Anti-IL-23p19 Antibody

Oruka Therapeutics to be Added to the Nasdaq Biotechnology Index (NBI)

Dec 18, 2024, 7:00 AM EST - 11 months ago

Oruka Therapeutics to be Added to the Nasdaq Biotechnology Index (NBI)

Oruka Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Nov 13, 2024, 4:25 PM EST - 1 year ago

Oruka Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Oruka Therapeutics to Present at Multiple November Investor Conferences

Nov 4, 2024, 7:00 AM EST - 1 year ago

Oruka Therapeutics to Present at Multiple November Investor Conferences

Oruka Therapeutics Announces Preclinical Data for ORKA-001 at the European Academy of Dermatology and Venereology Congress

Sep 25, 2024, 7:08 AM EDT - 1 year ago

Oruka Therapeutics Announces Preclinical Data for ORKA-001 at the European Academy of Dermatology and Venereology Congress

Oruka Therapeutics Announces $200 Million Private Placement

Sep 12, 2024, 7:05 AM EDT - 1 year ago

Oruka Therapeutics Announces $200 Million Private Placement

ARCA biopharma Announces Completion of Merger with Oruka Therapeutics and Implementation of Reverse Stock Split

Aug 29, 2024, 4:50 PM EDT - 1 year ago

ARCA biopharma Announces Completion of Merger with Oruka Therapeutics and Implementation of Reverse Stock Split

ARCA biopharma Provides Update Regarding Special Dividend Amount in Connection with the Proposed Merger with Oruka Therapeutics

Aug 26, 2024, 7:30 PM EDT - 1 year ago

ARCA biopharma Provides Update Regarding Special Dividend Amount in Connection with the Proposed Merger with Oruka Therapeutics

ARCA biopharma Announces 1-for-12 Reverse Stock Split in Connection with the Proposed Merger with Oruka Therapeutics

Aug 23, 2024, 4:30 PM EDT - 1 year ago

ARCA biopharma Announces 1-for-12 Reverse Stock Split in Connection with the Proposed Merger with Oruka Therapeutics

ARCA biopharma Declares Special Dividend in Connection with the Proposed Merger with Oruka Therapeutics

Aug 16, 2024, 4:15 PM EDT - 1 year ago

ARCA biopharma Declares Special Dividend in Connection with the Proposed Merger with Oruka Therapeutics

ARCA biopharma Announces Second Quarter 2024 Financial Results and Provides Corporate Update

Aug 1, 2024, 4:15 PM EDT - 1 year ago

ARCA biopharma Announces Second Quarter 2024 Financial Results and Provides Corporate Update

ARCA BIOPHARMA INVESTOR ALERT By the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of ARCA biopharma, Inc. - ABIO

May 10, 2024, 6:34 PM EDT - 1 year ago

ARCA BIOPHARMA INVESTOR ALERT By the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of ARCA biopharma, Inc. - ABIO

ARCA biopharma Announces First Quarter 2024 Financial Results and Provides Corporate Update

Apr 25, 2024, 4:15 PM EDT - 1 year ago

ARCA biopharma Announces First Quarter 2024 Financial Results and Provides Corporate Update

ARCA BIOPHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of ARCA biopharma, Inc. - ABIO

Apr 5, 2024, 1:27 PM EDT - 1 year ago

ARCA BIOPHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of ARCA biopharma, Inc. - ABIO

Arca Biopharma stock ($ABIO) soars on merger news

Apr 3, 2024, 11:38 AM EDT - 1 year ago

Arca Biopharma stock ($ABIO) soars on merger news

ARCA biopharma and Oruka Therapeutics Announce Merger Agreement

Apr 3, 2024, 7:30 AM EDT - 1 year ago

ARCA biopharma and Oruka Therapeutics Announce Merger Agreement

ARCA biopharma Announces 2023 Financial Results

Feb 1, 2024, 4:35 PM EST - 1 year ago

ARCA biopharma Announces 2023 Financial Results

ARCA biopharma Announces Third Quarter 2023 Financial Results

Oct 18, 2023, 4:25 PM EDT - 2 years ago

ARCA biopharma Announces Third Quarter 2023 Financial Results

ARCA biopharma Announces Second Quarter 2023 Financial Results

Jul 21, 2023, 4:25 PM EDT - 2 years ago

ARCA biopharma Announces Second Quarter 2023 Financial Results

ARCA biopharma Announces First Quarter 2023 Financial Results

Apr 24, 2023, 4:25 PM EDT - 2 years ago

ARCA biopharma Announces First Quarter 2023 Financial Results

ARCA biopharma Announces 2022 Financial Results and Provides Corporate Update

Feb 24, 2023, 4:20 PM EST - 2 years ago

ARCA biopharma Announces 2022 Financial Results and Provides Corporate Update

James Flynn Joins ARCA biopharma Board of Directors

Dec 19, 2022, 4:05 PM EST - 3 years ago

James Flynn Joins ARCA biopharma Board of Directors

ARCA biopharma Announces Third Quarter 2022 Financial Results

Oct 28, 2022, 4:15 PM EDT - 3 years ago

ARCA biopharma Announces Third Quarter 2022 Financial Results

ARCA biopharma Announces Second Quarter 2022 Financial Results

Aug 2, 2022, 4:15 PM EDT - 3 years ago

ARCA biopharma Announces Second Quarter 2022 Financial Results

Jacob Ma-Weaver Joins ARCA biopharma Board of Directors

Jun 21, 2022, 4:05 PM EDT - 3 years ago

Jacob Ma-Weaver Joins ARCA biopharma Board of Directors

ARCA biopharma Retains Ladenburg Thalmann to Support Strategic Options Review

May 5, 2022, 4:15 PM EDT - 3 years ago

ARCA biopharma Retains Ladenburg Thalmann to Support Strategic Options Review

ARCA biopharma: Activist's Pressure Could Make This Into A Liquidation Play

May 3, 2022, 11:50 AM EDT - 3 years ago

ARCA biopharma: Activist's Pressure Could Make This Into A Liquidation Play

ARCA biopharma Announces First Quarter 2022 Financial Results

May 2, 2022, 4:15 PM EDT - 3 years ago

ARCA biopharma Announces First Quarter 2022 Financial Results

ARCA biopharma Establishes Special Committee of the Board of Directors

Apr 18, 2022, 4:30 PM EDT - 3 years ago

ARCA biopharma Establishes Special Committee of the Board of Directors

ARCA biopharma's Tissue Factor Inhibitor Disappoints In Mid-Stage COVID-19 Study

Apr 1, 2022, 7:21 AM EDT - 3 years ago

ARCA biopharma's Tissue Factor Inhibitor Disappoints In Mid-Stage COVID-19 Study

ARCA biopharma Reports Topline Results for ASPEN-COVID-19 Phase 2b Clinical Trial

Mar 31, 2022, 4:15 PM EDT - 3 years ago

ARCA biopharma Reports Topline Results for ASPEN-COVID-19 Phase 2b Clinical Trial

ARCA biopharma Announces 2021 Financial Results and Provides Corporate Update

Mar 14, 2022, 4:15 PM EDT - 3 years ago

ARCA biopharma Announces 2021 Financial Results and Provides Corporate Update

Data on Gencaro Impact on Prevention of Bradycardia Published in Heart Rhythm O2

Jan 4, 2022, 8:30 AM EST - 4 years ago

Data on Gencaro Impact on Prevention of Bradycardia Published in Heart Rhythm O2

ARCA biopharma Announces Completion of Enrollment in Phase 2b ASPEN-COVID-19 Clinical Trial Evaluating rNAPc2 as a Potential Treatment for Patients Hospitalized with COVID-19

Dec 2, 2021, 8:30 AM EST - 4 years ago

ARCA biopharma Announces Completion of Enrollment in Phase 2b ASPEN-COVID-19 Clinical Trial Evaluating rNAPc2 as a Potential Treatment for Patients Hospitalized with COVID-19

ARCA biopharma to Present at the Q4 Virtual Investor Summit on November 17th

Nov 9, 2021, 4:15 PM EST - 4 years ago

ARCA biopharma to Present at the Q4 Virtual Investor Summit on November 17th

fedeblu
fedeblu Oct. 20 at 5:00 PM
$ORKA give me 30!
0 · Reply
Pika_Capital
Pika_Capital Oct. 14 at 4:59 PM
$ORKA pay attention to amount of watchers ;)
0 · Reply
Pika_Capital
Pika_Capital Oct. 14 at 2:44 PM
$ORKA $APGE $SYRE reminder
0 · Reply
fedeblu
fedeblu Oct. 14 at 2:39 PM
$ORKA booommm
0 · Reply
thesheiktrader
thesheiktrader Oct. 14 at 2:39 PM
$ORKA join papa Noel for Christmas
0 · Reply
fedeblu
fedeblu Oct. 13 at 1:05 PM
$ORKA boom
0 · Reply
JarvisFlow
JarvisFlow Oct. 13 at 12:08 PM
Barclays has adjusted their stance on Oruka Therapeutics ( $ORKA ), setting the rating to Overweight with a target price of 48.
0 · Reply
LudicrousReturns
LudicrousReturns Oct. 10 at 1:18 PM
09 OCT 2025 Ludicrous Returns Stock Model Update New Buy Now: $IDAI, $ORKA, $BURU
0 · Reply
LanjutTBK
LanjutTBK Oct. 10 at 8:11 AM
$ORKA looks like $28 is next resistance
0 · Reply
thesheiktrader
thesheiktrader Oct. 9 at 8:03 PM
$ORKA do I miss?
1 · Reply
thesheiktrader
thesheiktrader Oct. 9 at 8:01 PM
$ORKA jejeje
0 · Reply
thesheiktrader
thesheiktrader Oct. 9 at 8:00 PM
$ORKA cry cry
0 · Reply
Pika_Capital
Pika_Capital Oct. 9 at 4:25 PM
$ORKA $APGE $SYRE every day of waiting costs you 💰💰
1 · Reply
fedeblu
fedeblu Oct. 8 at 8:04 PM
$ORKA fantastic day and fantastic closure of temer day. Now only volumes are missing, when we wil get them…. We will reach The Sky 👌👌
0 · Reply
Pika_Capital
Pika_Capital Oct. 8 at 4:53 PM
$ORKA $APGE $SYRE reminder 🚀
0 · Reply
fedeblu
fedeblu Oct. 8 at 3:21 PM
$ORKA
0 · Reply
fedeblu
fedeblu Oct. 8 at 3:20 PM
$ORKA step by step, next challenging target 30 usd
0 · Reply
thesheiktrader
thesheiktrader Oct. 7 at 10:56 AM
$ORKA this week 25
1 · Reply
WhitelistWizard
WhitelistWizard Oct. 5 at 3:58 PM
$ORKA Technology services niche. Thin volume trading. No technical edge. Avoid.
0 · Reply
AStrokeOfLuck
AStrokeOfLuck Oct. 3 at 10:48 PM
$ORKA
0 · Reply
SweepCastApp
SweepCastApp Oct. 2 at 11:18 AM
$ORKA: Unusual Options Activity Alerted PUT flow observed 500x contracts at Strike price of $15 Exp on 11/21/2025 with Premium of $40K and showing BULLISH Sentiment
0 · Reply
thesheiktrader
thesheiktrader Sep. 30 at 3:35 PM
$MLTX booombbbbbbbbbb $ORKA
0 · Reply